What type of study is this?

This is a Systematic Review study.

September 21, 2025Revista HematologíaOpen Access

CAR-T cells in hematologic disorders: acute myeloid leukemia - A systematic review of efficacy and safety

View Full Paper

Ask AI

Bookmark

CAR-T therapies targeting CLL-1 showed 60% survival response at 6.2 months in adults, indicating potential efficiency.
Emerging antigens like B7-H3 may address antigen escape, offering hope for improved outcomes in AML therapy.
Moderate efficacy associated with CD33 and CD123 were found, although linked to higher hematologic toxicities.
Challenges such as cost and infrastructure need addressing for CAR-T therapies to succeed in regions like Colombia.

No takes yet. Share an insight, caveat, or question.

Systematic review assesses CAR-T cell efficacy and safety in AML, highlighting antigen heterogeneity challenges.

Barreto et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark